Profile data is unavailable for this security.
About the company
Percheron Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel therapies for oncology and rare diseases. The Company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer. HMBD-002 is a recombinant humanized monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). VISTA is one of a number of novel immuno-oncology targets under investigation by pharmaceutical companies, with potential applications to a range of solid tumors and hematological malignancies.
- Revenue in AUD (TTM)371.10k
- Net income in AUD-14.92m
- Incorporated2000
- Employees8.00
- LocationPercheron Therapeutics LtdL30, Collins Place, 35 Collins StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39827-8999
- Fax+61 39859-7701
- Websitehttps://percherontx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hexima Ltd | 0.00 | -503.83k | 2.17m | -- | -- | -- | -- | -- | -0.0246 | -0.0246 | 0.00 | 0.0091 | 0.00 | -- | -- | -- | -26.34 | -72.86 | -28.49 | -144.87 | -- | -- | -- | -335.94 | -- | -- | 0.00 | -- | -100.00 | -- | 46.05 | -- | -- | -- |
| Argent BioPharma Ltd | 180.56k | -17.84m | 4.56m | -- | -- | -- | -- | 25.24 | -0.3292 | -0.3292 | 0.0032 | -0.1196 | 0.0272 | 0.2721 | 0.4238 | -- | -269.25 | -135.49 | -- | -380.42 | 24.06 | -45.51 | -9,882.75 | -764.45 | 0.1752 | -321.38 | -- | -- | -79.74 | -38.66 | -1.79 | -- | -70.28 | -- |
| BPH Global Ltd | 352.38k | -1.49m | 5.56m | 31.00 | -- | -- | -- | 15.78 | -0.0026 | -0.0026 | 0.0006 | -0.0014 | 0.8548 | 3.49 | 2.27 | -- | -360.76 | -76.32 | -- | -214.32 | 6.86 | 17.08 | -422.04 | -156.56 | 0.1995 | -43.14 | -- | -- | 220.43 | -13.56 | 24.87 | -- | -- | -- |
| Inhalerx Ltd | 837.55k | -1.33m | 5.91m | -- | -- | -- | -- | 7.06 | -0.006 | -0.006 | 0.0037 | -0.0041 | 0.8301 | -- | 2.50 | -- | -131.43 | -73.85 | -- | -100.32 | -- | -- | -158.33 | -369.19 | -- | -- | -- | -- | -66.38 | 21.67 | 16.21 | -- | -- | -- |
| Invion Ltd | 0.00 | -8.81m | 7.11m | 8.00 | -- | 0.8538 | -- | -- | -0.1183 | -0.1183 | 0.00 | 0.0972 | 0.00 | -- | -- | -- | -70.63 | -29.16 | -77.64 | -30.88 | -- | -- | -- | -147.34 | -- | -- | 0.00 | -- | -100.00 | -- | -56.50 | -- | -- | -- |
| Biotron Ltd | 0.00 | -318.57k | 8.11m | 4.00 | -- | 7.21 | -- | -- | -0.0004 | -0.0004 | 0.00 | 0.0004 | 0.00 | -- | -- | -- | -43.23 | -86.63 | -206.95 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 90.73 | -- | -- | -- |
| Vectus Biosystems Ltd | 18.77k | -1.78m | 8.28m | -- | -- | -- | -- | 441.24 | -0.0334 | -0.0334 | 0.0004 | -0.0048 | 0.0134 | -- | 0.0266 | -- | -126.57 | -79.19 | -247.24 | -189.44 | -- | -- | -9,468.62 | -10,165.01 | 0.9301 | -554.06 | -- | -- | -75.58 | 73.61 | 23.99 | -- | -- | -- |
| Percheron Therapeutics Ltd | 371.10k | -14.92m | 8.70m | 8.00 | -- | 0.8696 | -- | 23.44 | -0.0149 | -0.0149 | 0.0004 | 0.0092 | 0.0275 | -- | 0.2824 | -- | -110.67 | -79.28 | -153.98 | -96.61 | -- | -- | -4,021.00 | -3,694.96 | -- | -1,093.50 | 0.0026 | -- | -39.71 | 64.80 | -25.19 | -- | -6.74 | -- |
| Chimeric Therapeutics Ltd | 3.97m | -10.43m | 8.84m | -- | -- | 2.14 | -- | 2.23 | -0.0071 | -0.0071 | 0.0029 | 0.0009 | 0.2154 | -- | 1.73 | -- | -56.62 | -66.67 | -171.92 | -112.02 | 78.66 | -- | -262.83 | -2,013.07 | -- | -62.30 | 0.7162 | -- | -- | -- | 16.76 | -- | -- | -- |
| Invex Therapeutics Ltd | 461.52k | -476.87k | 9.02m | -- | -- | 1.72 | -- | 19.54 | -0.0063 | -0.0063 | 0.0061 | 0.0698 | 0.0797 | -- | 4.92 | -- | -8.23 | -15.04 | -8.72 | -15.74 | -- | -- | -103.33 | -419.12 | -- | -- | 0.00 | -- | -72.92 | 22.74 | 70.95 | -- | -- | -- |
| Imagion Biosystems Ltd | 1.06m | -2.20m | 11.77m | -- | -- | -- | -- | 11.15 | -0.0177 | -0.0177 | 0.0082 | -0.0192 | 1.45 | -- | 1,173.13 | -- | -302.58 | -76.63 | -- | -102.36 | -- | -- | -208.52 | -911.24 | -- | -0.7972 | -- | -- | -18.54 | 22.02 | 83.43 | -- | -- | -- |
| Nexsen Ltd | -100.00bn | -100.00bn | 11.78m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.44 | -- | -605,140.90 | -- | -- | -- |
| Adalta Ltd | 695.66k | -4.50m | 12.75m | -- | -- | -- | -- | 18.33 | -0.0059 | -0.0059 | 0.0009 | -0.0005 | 0.1804 | -- | 0.4992 | -- | -116.72 | -70.41 | -216.60 | -126.24 | -- | -- | -647.19 | -207.18 | -- | -75.41 | 1.51 | -- | -61.02 | -28.97 | 16.33 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Percheron Therapeutics Ltd's reporting currency: Australian Dollar AUD
5.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aliwa Funds Management Pty Ltd.as of 06 Jan 2025 | 55.00m | 5.06% |
| Platinum Investment Management Ltd.as of 18 Dec 2024 | 10.00m | 0.92% |
Data from 06 Jan 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
